Linafexor

DB18031InvestigationalSmall molecule

Linafexor: Overview.

Mechanism: Pharmacologically active on Bile acid receptor
Curator reviewed
Formula / weight: C₂₈H₂₅Cl₂FN₄O₄ · 571.43 g/mol (avg)
Also known as: 1,2,4-OXADIAZOL-5(2H)-ONE, 3-(4-(3-((5-CYCLOPROPYL-3-(2,6-DICHLOROPHENYL)-4-ISOXAZOLYL)METHOXY)-8-AZABICYCLO(3.2.1)OCT-8-YL)-2-FLUOROPHENYL)- · 3-(4-((3-endo)-3-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-2-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one
Code names: CS-0159

Resolves to

Compound

Structure

InChIKeyCEEANZUSISGCJL-VQFNDLOPSA-NSMILESFC1=CC(=CC=C1C1=NOC(=O)N1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCC1=C(ON=C1C1=C(Cl)C=CC=C1Cl)C1CC1

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Linafexor, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.